2024
Estimated Health and Economic Outcomes of Racial and Ethnic Tuberculosis Disparities in US-Born Persons
Swartwood N, Li Y, Regan M, Marks S, Barham T, Asay G, Cohen T, Hill A, Horsburgh C, Khan A, McCree D, Myles R, Salomon J, Self J, Menzies N. Estimated Health and Economic Outcomes of Racial and Ethnic Tuberculosis Disparities in US-Born Persons. JAMA Network Open 2024, 7: e2431988. PMID: 39254977, PMCID: PMC11388029, DOI: 10.1001/jamanetworkopen.2024.31988.Peer-Reviewed Original ResearchConceptsUS-born personsEthnic disparitiesCase-fatality rateTB deathsTB casesTB incidenceSex-adjusted incidenceNational TB surveillance dataTB surveillance dataQuality-adjusted life yearsDistrict of ColumbiaTB disparitiesHealth outcomesEconomic outcomesFuture healthOutcome of TBUS-bornTB outcomesEstimate healthLife yearsSocietal costsTB burdenSocietal perspectiveGeneralized additive regression modelsGoal attainmentCost-effectiveness and health impact of screening and treatment of Mycobacterium tuberculosis infection among formerly incarcerated individuals in Brazil: a Markov modelling study
van Lieshout Titan A, Klaassen F, Pelissari D, de Barros Silva J, Alves K, Alves L, Sanchez M, Bartholomay P, Johansen F, Croda J, Andrews J, Castro M, Cohen T, Vuik C, Menzies N. Cost-effectiveness and health impact of screening and treatment of Mycobacterium tuberculosis infection among formerly incarcerated individuals in Brazil: a Markov modelling study. The Lancet Global Health 2024, 12: e1446-e1455. PMID: 39151980, PMCID: PMC11339731, DOI: 10.1016/s2214-109x(24)00221-3.Peer-Reviewed Original ResearchConceptsDisability-adjusted life yearsTuberculosis preventive treatmentTuberculosis deathsHealth impactsImpact of screeningIntervention cost-effectivenessInfection screeningCost-effectiveNational Institutes of HealthHealth outcomesHealth gainsInstitutes of HealthQuantify health effectsTuberculosis casesCost-effectiveness ratioTreatment of Mycobacterium tuberculosis infectionPotential health impactsLife yearsGreater health benefitsTuberculosis preventionTarget populationMonths of isoniazidMarkov modelling studiesHealth statesHealthPhylogeographic Analysis of Mycobacterium kansasii Isolates from Patients with M. kansasii Lung Disease in Industrialized City, Taiwan - Volume 30, Number 8—August 2024 - Emerging Infectious Diseases journal - CDC
Cudahy P, Liu P, Warren J, Sobkowiak B, Yang C, Ioerger T, Wu C, Lu P, Wang J, Chang H, Huang H, Cohen T, Lin H. Phylogeographic Analysis of Mycobacterium kansasii Isolates from Patients with M. kansasii Lung Disease in Industrialized City, Taiwan - Volume 30, Number 8—August 2024 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2024, 30: 1562-1570. PMID: 39043390, PMCID: PMC11286038, DOI: 10.3201/eid3008.240021.Peer-Reviewed Original ResearchConceptsM. kansasii lung diseaseM. kansasii pulmonary diseasePulmonary diseaseM. kansasii isolatesSputum mycobacterial cultureWhole-genome sequencingEvaluate risk factorsPhylogeographic analysisAge of participantsGenetic relatednessEnvironmental acquisitionLung diseaseMycobacterial cultureOdds ratioRisk factorsM. kansasiiPatientsDiseasePlantsEnvironmental transmissionIsolatesPark plantingsCDCRiskRisk factors underlying racial and ethnic disparities in tuberculosis diagnosis and treatment outcomes, 2011–19: a multiple mediation analysis of national surveillance data
Regan M, Barham T, Li Y, Swartwood N, Beeler Asay G, Cohen T, Horsburgh C, Khan A, Marks S, Myles R, Salomon J, Self J, Winston C, Menzies N. Risk factors underlying racial and ethnic disparities in tuberculosis diagnosis and treatment outcomes, 2011–19: a multiple mediation analysis of national surveillance data. The Lancet Public Health 2024, 9: e564-e572. PMID: 39095133, DOI: 10.1016/s2468-2667(24)00151-8.Peer-Reviewed Original ResearchConceptsUS-born individualsNon-US-born individualsHispanic individualsTract-level povertyTract-level measuresEthnic disparitiesCensus tract levelCensus tract-level povertyEconomic segregationEvidence of disparitiesAnalysis of national surveillance dataBlack individualsTuberculosis outcomesNeighborhood-level social vulnerabilityTract levelUS-bornSocial vulnerabilityUS National Tuberculosis Surveillance SystemNational Tuberculosis Surveillance SystemHigh riskCensusNational surveillance dataTuberculosis Surveillance SystemCase managementReduce disparitiesPredictors of unsuccessful tuberculosis treatment outcomes in Brazil: an analysis of 259,484 patient records
Ryuk D, Pelissari D, Alves K, Oliveira P, Castro M, Cohen T, Sanchez M, Menzies N. Predictors of unsuccessful tuberculosis treatment outcomes in Brazil: an analysis of 259,484 patient records. BMC Infectious Diseases 2024, 24: 531. PMID: 38802744, PMCID: PMC11129366, DOI: 10.1186/s12879-024-09417-7.Peer-Reviewed Original ResearchConceptsTreatment outcomesFactors associated with unsuccessful treatment outcomesHigher risk of poor treatment outcomeTB treatmentRisk of poor treatment outcomesUnsuccessful treatmentEffectiveness of TB treatmentAssociated with unsuccessful treatmentUnsuccessful treatment outcomesTuberculosis treatment outcomesDrug-susceptible TBHealth system levelMultivariate logistic regression modelService-related factorsTB drug resistanceComorbid health conditionsHealth-related behaviorsCategorizing treatment outcomesPatient-level factorsClinical examination resultsNational Disease Notification SystemPoor treatment outcomesDisease notification systemHIV infectionLogistic regression models
2021
Comparison of Estimated Effectiveness of Case-Based and Population-Based Interventions on COVID-19 Containment in Taiwan
Ng TC, Cheng HY, Chang HH, Liu CC, Yang CC, Jian SW, Liu DP, Cohen T, Lin HH. Comparison of Estimated Effectiveness of Case-Based and Population-Based Interventions on COVID-19 Containment in Taiwan. JAMA Internal Medicine 2021, 181: 913-921. PMID: 33821922, PMCID: PMC8025126, DOI: 10.1001/jamainternmed.2021.1644.Peer-Reviewed Original ResearchConceptsPopulation-based interventionsCOVID-19 casesCOVID-19 controlComparative effectiveness research studyComparative effectiveness studiesEffective public health systemCOVID-19Reproduction numberPublic health professionalsPublic health systemCategories of interventionsStochastic branching process modelCase detectionMAIN OUTCOMESubsequent infectionPresymptomatic stagePrimary casesHealth professionalsEffective reproduction numberEstimated EffectivenessSerial intervalEffectiveness studiesHealth systemContact tracingCOVID-19 containment
2020
High-resolution estimates of tuberculosis incidence among non-U.S.-born persons residing in the United States, 2000–2016
Hill AN, Cohen T, Salomon JA, Menzies NA. High-resolution estimates of tuberculosis incidence among non-U.S.-born persons residing in the United States, 2000–2016. Epidemics 2020, 33: 100419. PMID: 33242759, PMCID: PMC7808561, DOI: 10.1016/j.epidem.2020.100419.Peer-Reviewed Original ResearchConceptsIncidence risk ratioTuberculosis incidence rateIncidence rateTuberculosis riskTuberculosis casesNational Tuberculosis Surveillance SystemTuberculosis prevention effortsNew tuberculosis casesLow incidence rateTuberculosis Surveillance SystemBirth countryTuberculosis incidenceRisk ratioTuberculosis trendsHigh-income countriesYounger agePrevention effortsEffective targetingCohortEntry yearCommunity surveySurveillance systemRegression modelsAgeUnited StatesRisk factors for recurrent tuberculosis after successful treatment in a high burden setting: a cohort study
Cudahy PGT, Wilson D, Cohen T. Risk factors for recurrent tuberculosis after successful treatment in a high burden setting: a cohort study. BMC Infectious Diseases 2020, 20: 789. PMID: 33097000, PMCID: PMC7585300, DOI: 10.1186/s12879-020-05515-4.Peer-Reviewed Original ResearchConceptsM. tuberculosis infectionRecurrent tuberculosisSuccessful treatmentTuberculosis recurrenceHazard ratioSmear gradeTuberculosis infectionRisk factorsSmear-positive pulmonary tuberculosisCox proportional hazards modelSputum smear gradeRepetitive unit-variable number tandem repeat (MIRU-VNTR) typingHigh-burden settingsRisk of recurrenceProportional hazards modelSuccessful treatment completionRecurrent diseaseCohort studyPulmonary tuberculosisBurden settingsClinical presentationRecurrent episodesInitial episodeNumber tandem repeat typingTreatment completionTransmission Modeling with Regression Adjustment for Analyzing Household-based Studies of Infectious Disease: Application to Tuberculosis.
Crawford FW, Marx FM, Zelner J, Cohen T. Transmission Modeling with Regression Adjustment for Analyzing Household-based Studies of Infectious Disease: Application to Tuberculosis. Epidemiology 2020, 31: 238-247. PMID: 31764276, PMCID: PMC7718772, DOI: 10.1097/ede.0000000000001143.Peer-Reviewed Original ResearchConceptsSusceptible household contactsHousehold contactsTB casesBacillus Calmette-Guérin (BCG) vaccinationInfected household contactsIsoniazid preventive therapyActive tuberculosis casesCulture-positive casesRisk of diseaseCohort studyMicrobiological confirmationPreventive therapyTuberculosis casesRisk factorsInfection resultsAdult contactsInfection riskInfectious diseasesLogistic regressionRate of transmissionTransmissible diseasesDiseaseIndividual-level characteristicsHigher hazardDisease susceptibilityComparative Modeling of Tuberculosis Epidemiology and Policy Outcomes in California
Menzies NA, Parriott A, Shrestha S, Dowdy DW, Cohen T, Salomon JA, Marks SM, Hill AN, Winston CA, Asay GR, Barry P, Readhead A, Flood J, Kahn JG, Shete PB. Comparative Modeling of Tuberculosis Epidemiology and Policy Outcomes in California. American Journal Of Respiratory And Critical Care Medicine 2020, 201: 356-365. PMID: 31626560, PMCID: PMC7464931, DOI: 10.1164/rccm.201907-1289oc.Peer-Reviewed Original ResearchConceptsTB incidenceTB casesAdditional interventionsTuberculosis epidemiologyPublic health prioritizationTreatment of LTBIInfection control interventionsPotential intervention effectsLTBI testingTB servicesLTBI diagnosisLTBI prevalenceAverage annual declineEpidemiologic projectionsSustained reductionTreatment interventionsControl interventionsTB determinantsDefinitive dataIntervention effectsAnnual declineLocal transmissionIncidenceLTBIIntervention
2019
Transmissibility and potential for disease progression of drug resistant Mycobacterium tuberculosis: prospective cohort study
Becerra MC, Huang CC, Lecca L, Bayona J, Contreras C, Calderon R, Yataco R, Galea J, Zhang Z, Atwood S, Cohen T, Mitnick CD, Farmer P, Murray M. Transmissibility and potential for disease progression of drug resistant Mycobacterium tuberculosis: prospective cohort study. The BMJ 2019, 367: l5894. PMID: 31649017, PMCID: PMC6812583, DOI: 10.1136/bmj.l5894.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntitubercular AgentsChildChild, PreschoolContact TracingDisease ProgressionFemaleFollow-Up StudiesHumansIncidenceInfantInfant, NewbornIsoniazidKaplan-Meier EstimateMaleMicrobial Sensitivity TestsMiddle AgedMycobacterium tuberculosisPeruProspective StudiesRifampinSputumTuberculin TestTuberculosis, Multidrug-ResistantTuberculosis, PulmonaryYoung AdultConceptsDrug-sensitive tuberculosisMultidrug-resistant tuberculosisHousehold contactsProspective cohort studySensitive tuberculosisTuberculosis infectionResistant tuberculosisCohort studyTuberculosis diseaseHigh riskDrug-resistant Mycobacterium tuberculosisIncident tuberculosis diseasePhenotypic drug resistanceDistrict Health CenterResistant Mycobacterium tuberculosisDrug-susceptible strainsDrug resistance profilesActive diseasePulmonary tuberculosisDisease progressionGuideline producersHealth centersIndex patientsEffective treatmentPatients
2018
Trends in C-Reactive Protein, D-Dimer, and Fibrinogen during Therapy for HIV-Associated Multidrug-Resistant Tuberculosis.
Cudahy PGT, Warren JL, Cohen T, Wilson D. Trends in C-Reactive Protein, D-Dimer, and Fibrinogen during Therapy for HIV-Associated Multidrug-Resistant Tuberculosis. American Journal Of Tropical Medicine And Hygiene 2018, 99: 1336-1341. PMID: 30226135, PMCID: PMC6221241, DOI: 10.4269/ajtmh.18-0322.Peer-Reviewed Original ResearchConceptsC-reactive proteinMulti-drug resistant tuberculosisD-dimerMedian C-reactive proteinSerum C-reactive proteinHigher baseline fibrinogenMDR-TB therapyHIV-positive adultsDrug-resistant tuberculosisHIV-positive participantsHigher CRP concentrationsEarly treatment modificationBaseline fibrinogenTreatment initiationResistant tuberculosisCRP concentrationsTreatment modificationTreatment outcomesTreatment responseHigh riskHigh mortalityNormal levelsOlder ageEarly responseFibrinogenInvestigating spillover of multidrug-resistant tuberculosis from a prison: a spatial and molecular epidemiological analysis
Warren JL, Grandjean L, Moore DAJ, Lithgow A, Coronel J, Sheen P, Zelner JL, Andrews JR, Cohen T. Investigating spillover of multidrug-resistant tuberculosis from a prison: a spatial and molecular epidemiological analysis. BMC Medicine 2018, 16: 122. PMID: 30071850, PMCID: PMC6091024, DOI: 10.1186/s12916-018-1111-x.Peer-Reviewed Original ResearchInternal migration and transmission dynamics of tuberculosis in Shanghai, China: an epidemiological, spatial, genomic analysis
Yang C, Lu L, Warren JL, Wu J, Jiang Q, Zuo T, Gan M, Liu M, Liu Q, DeRiemer K, Hong J, Shen X, Colijn C, Guo X, Gao Q, Cohen T. Internal migration and transmission dynamics of tuberculosis in Shanghai, China: an epidemiological, spatial, genomic analysis. The Lancet Infectious Diseases 2018, 18: 788-795. PMID: 29681517, PMCID: PMC6035060, DOI: 10.1016/s1473-3099(18)30218-4.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overChinaDisease Transmission, InfectiousFemaleGenotypeHumansMaleMiddle AgedMinisatellite RepeatsMolecular EpidemiologyMycobacterium tuberculosisPolymorphism, Single NucleotideRural PopulationSpatial AnalysisTransients and MigrantsTuberculosisUrban PopulationWhole Genome SequencingConceptsM tuberculosisEpidemiological dataSingle nucleotide polymorphismsCulture-positive Mycobacterium tuberculosis isolatesCulture-positive tuberculosisPopulation-based studyMycobacterium tuberculosis isolatesTransmission dynamicsTime of infectionDynamics of tuberculosisTuberculosis controlUS National InstitutesTuberculosis isolatesMore effective interventionsProximity of residenceRecent transmissionPatient's homeTuberculosisLocal transmission dynamicsEffective interventionsLocal transmissionLocal incidenceNational InstituteVNTR patternsWhole-genome sequencing
2017
Polyclonal Pulmonary Tuberculosis Infections and Risk for Multidrug Resistance, Lima, Peru - Volume 23, Number 11—November 2017 - Emerging Infectious Diseases journal - CDC
Nathavitharana RR, Shi CX, Chindelevitch L, Calderon R, Zhang Z, Galea JT, Contreras C, Yataco R, Lecca L, Becerra MC, Murray MB, Cohen T. Polyclonal Pulmonary Tuberculosis Infections and Risk for Multidrug Resistance, Lima, Peru - Volume 23, Number 11—November 2017 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2017, 23: 1887-1890. PMID: 29048297, PMCID: PMC5652442, DOI: 10.3201/eid2311.170077.Peer-Reviewed Original ResearchConceptsTreatment of tuberculosisHost Mycobacterium tuberculosis diversityMultidrug-resistant TBInfectious Diseases journal - CDCPulmonary TB patientsPulmonary tuberculosis infectionTB patientsTuberculosis infectionPolyclonal infectionsSimple infectionMultidrug resistanceInfectionPatientsTuberculosisPrevalenceDiagnosisProtective effects of household-based TB interventions are robust to neighbourhood-level variation in exposure risk in Lima, Peru: a model-based analysis
Zelner J, Murray M, Becerra M, Galea J, Lecca L, Calderon R, Yataco R, Zhang Z, Cohen T. Protective effects of household-based TB interventions are robust to neighbourhood-level variation in exposure risk in Lima, Peru: a model-based analysis. International Journal Of Epidemiology 2017, 47: 185-192. PMID: 29025111, DOI: 10.1093/ije/dyx171.Peer-Reviewed Original ResearchConceptsIsoniazid preventive therapyLatent TB infectionTB casesHousehold contactsHousehold exposureTB diseaseHealth centersPopulation-based prospective cohort studyHigh-risk household contactsMore casesBlanket screeningIncident pulmonary tuberculosisIncident TB diseasePositive household contactsProspective cohort studyTB screening programPublic Health CenterIncident tuberculosisTB infectionCohort studyPreventive therapyPulmonary tuberculosisTB incidenceSkin testTB risk
2016
Genomic diversity in autopsy samples reveals within-host dissemination of HIV-associated Mycobacterium tuberculosis
Lieberman TD, Wilson D, Misra R, Xiong LL, Moodley P, Cohen T, Kishony R. Genomic diversity in autopsy samples reveals within-host dissemination of HIV-associated Mycobacterium tuberculosis. Nature Medicine 2016, 22: 1470-1474. PMID: 27798613, PMCID: PMC5508070, DOI: 10.1038/nm.4205.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAutopsyBacteriological TechniquesCoinfectionDNA, BacterialFemaleGenetic VariationHIV InfectionsHumansLiverLungLymph NodesMaleMiddle AgedMycobacterium tuberculosisPhylogenyPolymorphism, Single NucleotideSouth AfricaSpleenTuberculosisTuberculosis, HepaticTuberculosis, Lymph NodeTuberculosis, PulmonaryTuberculosis, SplenicRapid Drug Susceptibility Testing of Drug-Resistant Mycobacterium tuberculosis Isolates Directly from Clinical Samples by Use of Amplicon Sequencing: a Proof-of-Concept Study
Colman RE, Anderson J, Lemmer D, Lehmkuhl E, Georghiou SB, Heaton H, Wiggins K, Gillece JD, Schupp JM, Catanzaro DG, Crudu V, Cohen T, Rodwell TC, Engelthaler DM. Rapid Drug Susceptibility Testing of Drug-Resistant Mycobacterium tuberculosis Isolates Directly from Clinical Samples by Use of Amplicon Sequencing: a Proof-of-Concept Study. Journal Of Clinical Microbiology 2016, 54: 2058-2067. PMID: 27225403, PMCID: PMC4963505, DOI: 10.1128/jcm.00535-16.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overChildChild, PreschoolFemaleGenotyping TechniquesHigh-Throughput Nucleotide SequencingHumansMaleMicrobial Sensitivity TestsMiddle AgedMycobacterium tuberculosisPharmaceutical PreparationsPilot ProjectsSequence Analysis, DNASpecimen HandlingSputumTime FactorsYoung AdultConceptsDrug-resistant tuberculosisPatient sputum samplesDrug resistance profilesSputum samplesDrug-resistant Mycobacterium tuberculosis isolatesPhenotypic drug susceptibility testing resultsDrug susceptibility testing resultsEvidence-based treatment plansResistance profilesMajor global health concernRapid drug susceptibility testingMycobacterium tuberculosis isolatesNext-generation sequencingClinical samplesAmplification of resistanceDrug susceptibility testingTargeted Next-Generation SequencingMycobacterium tuberculosis DNAGlobal health concernSusceptibility testing resultsSame clinical samplePhenotypic DSTInfectious causesTreatment outcomesTuberculosis isolatesUse of Lot Quality Assurance Sampling to Ascertain Levels of Drug Resistant Tuberculosis in Western Kenya
Jezmir J, Cohen T, Zignol M, Nyakan E, Hedt-Gauthier BL, Gardner A, Kamle L, Injera W, Carter EJ. Use of Lot Quality Assurance Sampling to Ascertain Levels of Drug Resistant Tuberculosis in Western Kenya. PLOS ONE 2016, 11: e0154142. PMID: 27167381, PMCID: PMC4864281, DOI: 10.1371/journal.pone.0154142.Peer-Reviewed Original ResearchConceptsMDR-TBDrug resistanceResistant tuberculosisLot Quality Assurance Sampling methodologyMulti-drug resistant tuberculosisPositive TB patientsDrug resistance surveillanceDrug-resistant tuberculosisTB drug resistanceRural settingsPoly-resistant strainsTB patientsWestern KenyaLot Quality AssuranceLow prevalencePatientsResistance surveillancePrevalenceTuberculosisLQASSettingLow levelsDifferent geographic settingsUrban settingsLevelsAssessing Local Risk of Rifampicin-Resistant Tuberculosis in KwaZulu-Natal, South Africa Using Lot Quality Assurance Sampling
Heidebrecht CL, Podewils LJ, Pym A, Mthiyane T, Cohen T. Assessing Local Risk of Rifampicin-Resistant Tuberculosis in KwaZulu-Natal, South Africa Using Lot Quality Assurance Sampling. PLOS ONE 2016, 11: e0153143. PMID: 27050561, PMCID: PMC4822784, DOI: 10.1371/journal.pone.0153143.Peer-Reviewed Original ResearchConceptsIncident TB casesTB casesResistant TBDrug-resistant TB casesRifampicin-resistant tuberculosisMultidrug-resistant tuberculosisDrug susceptibility testingRIF-resistant TBLot Quality Assurance SamplingQuality assurance samplingResistant diseaseHigh burdenRIF resistanceKwaZulu-NatalSusceptibility testingHigh-risk areasTuberculosisRiskGreater proportionBurdenTBDiseaseGeographic heterogeneityCasesRifampicin